Gilead's New Daily HIV Pill, Bixlenvo, Approved by FDA to Simplify Treatment Regimens

New York, NY - The U.S. Food and Drug Administration (FDA) has granted approval for Gilead Sciences' (NASDAQ: GILD) new once-daily HIV pill, Bixlenvo. This novel medication is designed to streamline treatment for certain HIV patients, particularly those whose viral load is suppressed but are currently on more complex drug regimens.

Simplifying Care for HIV Patients

Bixlenvo combines bictegravir, a key component of Gilead's successful Biktarvy HIV medication, with lenacapavir, a first-in-class capsid inhibitor that plays a central role in Gilead's long-term HIV treatment and prevention strategy. This single-tablet regimen offers a simplified option for adults with HIV who are maintaining viral suppression but face challenges with existing single-pill treatments due to factors like drug resistance, side effects, or interactions with other medications.

The new pill is also a viable alternative for individuals who are managing their HIV with a single-tablet regimen, such as Biktarvy, and wish to switch to a new treatment option. Gilead estimates that this specific patient population represents approximately 5% or more of individuals living with HIV in the United States.

Addressing Unmet Needs in HIV Management

Dr. Jared Baeten, Gilead's head of clinical development and virology, highlighted that Bixlenvo addresses a significant unmet need, especially for patients on complex regimens who can now consolidate their treatment into a more manageable form. "It's also meaningful for individuals who are seeking options for something new," Dr. Baeten stated. "We want to build options that give people the opportunity to choose something that's going to work for them and work for them for the long haul."

For decades, managing HIV has involved daily pills, a treatment approach pioneered by Gilead. However, some patients require more intricate combinations due to virus resistance, adverse reactions, or drug interactions, often leading to multiple daily pills and complex dosing schedules. This is particularly relevant for older individuals living with HIV who may have long treatment histories and face age-related health complications.

Clinical Trial Success and Patient Testimonials

The approval of Bixlenvo is supported by two Phase 3 trials, ARTISTRY-1 and another study, which demonstrated the pill's efficacy in maintaining viral suppression at 48 weeks, comparable to previous regimens. The drug was generally well-tolerated, with common side effects including headache, nausea, and diarrhea. Importantly, no new safety concerns were identified.

Timothy Cameron, a 64-year-old living with HIV for over 40 years, shared his positive experience as a participant in the ARTISTRY-1 trial. Having previously navigated numerous medications and developed drug resistance, Cameron found Bixlenvo to be a game-changer. "It's one less thing I'm putting in my body, and it preserves options if I need them," he said, emphasizing the simplification of his treatment and the continued effectiveness against his virus.

Pricing and Accessibility

The list price for Bixlenvo is $4,595 for a 30-day supply, which is comparable to existing daily single-tablet HIV treatments. Gilead offers patient assistance programs to help individuals without health insurance receive the medication for free, and co-pay support for those with commercial or private insurance.

Gilead's Broader HIV Strategy

Bixlenvo is a key component of Gilead's comprehensive strategy to offer a diverse range of HIV treatment options centered around lenacapavir. This includes daily pills, weekly oral regimens, and long-acting injectables, aiming to provide patients with the flexibility to choose a management approach that best suits their lifestyle and preferences.